(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study

(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study

Bibliographic Details
Main Authors:	R. Valenti, C. Plantet, A. Tadmouri
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000953

Similar Items

P009 A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study
by: N. Harbeck, et al.
Published: (2023-03-01)

Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study
by: D. Lüftner, et al.
Published: (2021-04-01)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
by: Sara Alkhezayem, et al.
Published: (2020-08-01)

Adverse cutaneous effects of neratinib
by: Ramiz N. Hamid, et al.
Published: (2019-07-01)

Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)
by: R. Bartsch, et al.
Published: (2021-04-01)

The post-authorisation safety of COVID-19 vaccines: real-world evidence
by: Li, X
Published: (2024)

P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib
by: R. Bartsch, et al.
Published: (2023-03-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
by: Laurence Booth, et al.
Published: (2019-07-01)

Neratinib protects pancreatic beta cells in diabetes
by: Amin Ardestani, et al.
Published: (2019-11-01)

P006 Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)
by: S. González-Santiago, et al.
Published: (2023-03-01)

Real world safety of methoxyflurane analgesia in the emergency setting: a comparative hybrid prospective-retrospective post-authorisation safety study
by: Nawab Qizilbash, et al.
Published: (2023-08-01)

Profile of neratinib and its potential in the treatment of breast cancer
by: Feldinger K, et al.
Published: (2015-06-01)

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
by: Iwata, Hiroji, et al.
Published: (2019)

Neratinib for HER2-positive breast cancer with an overlooked option
by: Liting Guo, et al.
Published: (2023-10-01)

A European, multicentre, observational, post-authorisation safety study of oral sulphate solution: compliance and safety
by: Jaroslaw Regula, et al.
Published: (2020-02-01)

Study of Interactions of an Anticancer Drug Neratinib With Bovine Serum Albumin: Spectroscopic and Molecular Docking Approach
by: Tanveer A. Wani, et al.
Published: (2018-03-01)

Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
by: Paul Dent, et al.
Published: (2022-09-01)

Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer
by: Aparna Shinde, et al.
Published: (2022-06-01)

Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
by: Arlene Chan
Published: (2016-09-01)

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib
by: Stephanie N. Shishido, et al.
Published: (2022-02-01)

Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication
by: Javier Cid Ruzafa, et al.
Published: (2019-08-01)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
by: Chilà G, et al.
Published: (2021-06-01)

Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model
by: Hadeel Kheraldine, et al.
Published: (2023-12-01)

Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs
by: Michael Guy, et al.
Published: (2024-01-01)

Nursing experience of a breast cancer patient with diarrhea reaction after taking neratinib
by: BaoPing Luo, et al.
Published: (2023-09-01)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
by: James J. Harding, et al.
Published: (2023-02-01)

Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats
by: Kate R. Secombe, et al.
Published: (2022-08-01)

The calcium‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea
by: Taras Lysyy, et al.
Published: (2019-10-01)

Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: Protocol of a pilot study in England
by: De Lusignan, S, et al.
Published: (2017)

Authorisation for Fusafungine-Containing Medicines is Revoked
by: Z. A. Alacheva
Published: (2016-06-01)

Guidance on the renewal of the authorisation of feed additives
by: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), et al.
Published: (2021-01-01)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
by: Maria Luisa Brandi, et al.
Published: (2022-09-01)

The EGFR/ErbB inhibitor neratinib modifies the neutrophil phosphoproteome and promotes apoptosis and clearance by airway macrophages
by: Kimberly D. Herman, et al.
Published: (2022-07-01)

Challenges in development and authorisation of gene therapy products
by: A. A. Soldatov, et al.
Published: (2022-04-01)

Authorisation inconsistency in IoT third‐party integration
by: Jiongyi Chen, et al.
Published: (2022-03-01)

Electronic banking : pre-authorised payment systems
by: Lau, Kian Lee, et al.
Published: (2015)

Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results
by: A. Massot, et al.
Published: (2014-03-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
by: Arshad, M, et al.
Published: (2024)

Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer
by: Vasileios Angelis, et al.
Published: (2022-03-01)